One of the Micro-Cap pharmaceutical stocks engaged in manufacturing and marketing pharmaceutical and therapeutic products has hit a 5% upper circuit after reporting increased revenue by 235.66 percent YOY and a net profit increase of 353.54 percent YOY in Q2 FY25.
Share Price Movement
The share price of Trident Lifeline Limited hit a 5 percent upper circuit to Rs. 313.95 per share on Monday, a significant rise from its previous close of Rs. 299 per share. Over the past 6 months, the share has delivered returns of over 83 percent. The market capitalization now stands at approximately Rs. 361.02 crore as of October 21, 2024.
What Happened
Trident Lifeline Limited’s recent quarter saw a rise in revenue and net profits, which led to this bullish movement in the stock price. According to its recent filing, in the quarter ending September 2024, Trident Lifeline Limited’s consolidated revenue from operations has increased by 235.66 percent YOY, from Rs. 4.60 crore in Q2 FY24 to Rs. 15.45 crore in Q2 FY25, and grown by 11.96 percent QoQ from Rs. 13.80 crore in Q1 FY25.
The company’s consolidated net profit has increased by 353.54 percent, from Rs. 0.62 crore in Q2 FY24 to Rs. 2.81 crore in Q2 FY25. As compared to the last quarter of 2025, the company’s net profit is up by 75.51 percent QoQ from Rs. 1.60 crore.
The company’s EPS has increased by 35.18 percent, from Rs. 1.99 in Q1 FY25 to Rs. 2.69 in Q2 FY25. The EBITDA margin has improved by 82%.
In terms of return ratios, Trident Lifeline Limited’s share ROE and ROCE are currently at 12 percent and 14.7 percent, respectively. The company has a debt-to-equity ratio of 0.40x.
Shareholding Pattern:
As of the September 2024 shareholding pattern, Trident Lifeline Limited has majorly held a promoter by 62.99 percent, a foreign institutional investor by 6.09 percent, and the public by 30.92 percent.
Also read…
About the company
Trident Lifeline Limited was founded in 2014 and manufactures and markets pharmaceutical products across domestic and international markets. The company produces a diverse portfolio of 832 products, including tablets, capsules, and various pharmaceutical formulations.
Trident Lifeline Limited operates through an asset-light model, partnering with contract manufacturers to produce high-quality medications. The company operates in 25+ countries,
including Bolivia, Cambodia, Cameroon, Ghana, Kenya, and Venezuela. The company distributes its products through third-party networks and focuses on affordable, essential medications.
The company holds 411 export market registrations and actively pursues 1067 new registrations across different countries. It specializes in multiple therapeutic categories, including anti-bacterial, anti-diabetic, and anti-malarial medications. The company maintains high ethical standards in pharmaceutical marketing and prioritizes accessibility to essential medicines worldwide.
Written By- Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
Start Your Stock Market Journey Today!
Want to learn Stock Market trading and Investing? Make sure to check out exclusive Stock Market courses by FinGrad, the learning initiative by Trade Brains. You can enroll in FREE courses and webinars available on FinGrad today and get ahead in your trading career. Join now!!
